Pharmacopeia Inc

Pharmacopeia — Pharmacopeia Drug Discovery — CIBC World Markets conference 2007

29 slides from Pharmacopeia's conference presentation, Apr 11, 2007

  1. Slide 1: CIBC World Markets, April 11th, 2007

    Slide 1: CIBC World Markets, April 11th, 2007

    CIBC World Markets April 11th, 2007 Discovering excellence, driving clinical successTM

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which e

  3. Slide 3: Value Drivers - Balanced Risk

    Slide 3: Value Drivers - Balanced Risk

    Value Drivers - Balanced Risk Biopharmaceutical company Focused on cardiovascular and immunological diseases Deep pipeline of potential blockbusters 6 programs in active clinical development Leader in developing DARA – Phase 1 initiated 02/07 First-in-class dual-acting ARB and ERA for hypertension a

  4. Slide 4: Agenda for Today

    Slide 4: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

  5. Slide 5: One of the Deepest Portfolios in Biotech

    Slide 5: One of the Deepest Portfolios in Biotech

    Inflammation PS386113 Asthma/Allergy* VLA-4 PS460644 Angiogenesis a v b 3/ a v b 5 Parkinson’s Adenosine A2A Rheumatoid/MS CCR1 Derm/Ocular JAK3 Topical Immuno/Inflam JAK3 Inflammation PS873266 Respiratory PS948115 Oncology PS241541 Cardiovascular DARA PS433540 Metabolic Disease PS522501 Oncology PS

  6. Slide 6: Agenda for Today

    Slide 6: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

  7. Slide 7: CXCR2 Antagonists

    Slide 7: CXCR2 Antagonists

    CXCR2 Antagonists CXCR2 receptor expressed on neutrophils, monocytes and microvascular endothelial cells Multiple ligands – induced by IL-2, TNF a - including IL-8, GRO a attract immune cells to sites of inflammation Expected utility in inflammatory lung disease including COPD

  8. Slide 8: CXCR2 Antagonists - COPD

    Slide 8: CXCR2 Antagonists - COPD

    CXCR2 Antagonists COPD includes chronic bronchitis and emphysema By 2010, expected to be 3rd leading cause of death in US In 2001 there were > 12 million diagnoses Current market = ~$9 billion CXCR2 antagonist in clinical development with Schering-Plough Active against biomarker at 50 mg in voluntee

  9. Slide 9: Agenda for Today

    Slide 9: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

  10. Slide 10: p38 MAP Kinase Inhibitors Mechanism of Action

    Slide 10: p38 MAP Kinase Inhibitors Mechanism of Action

    p38 MAP Kinase Inhibitors Mechanism of Action MK2 TNF a IL-1 RA – anti IL-1 Kineret Expected to block the pro-inflammatory effects of TNF a , IL-1 b , IL-6 Expected utility in RA, COPD, Psoriasis & IBD

  11. Slide 11: p38 MAP Kinase Inhibitors

    Slide 11: p38 MAP Kinase Inhibitors

    p38 MAP Kinase Inhibitors p38 kinase inhibitors for inflammatory diseases RA target population of 2.1 million patients Current RA market $5.6B in US alone PS540466 approaching Phase 2 Well tolerated in multiple Phase 1 trials Currently in RA patients receiving methotrexate Back up compound entered P

  12. Slide 12: Agenda for Today

    Slide 12: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

  13. Slide 13: DARA – First-in-class

    Slide 13: DARA – First-in-class

    DARA – First-in-class DARA combines the properties of two marketed product classes Angiotensin II (Type 1) receptor blockers (ARBs) ETA selective endothelin receptor antagonists (ERAs) DARA could improve treatment of several cardiovascular diseases Dual Acting Angiotensin and Endothelin Receptor Ant

  14. Slide 14: ARB + ERA = Synergistic Combination

    Slide 14: ARB + ERA = Synergistic Combination

    ARB + ERA = Synergistic Combination Angiotensin II and Endothelin 1 Vasoconstriction Tissue proliferation and fibrosis Inflammation Preclinical Results - Hypertension Potent blockade of endothelin and angiotensin by oral route Potent BP lowering in two preclinical models predictive of activity in hy

  15. Slide 15: PS433540 – Potent as ARB and ERA

    Slide 15: PS433540 – Potent as ARB and ERA

    PS433540 – Potent as ARB and ERA PS-433540 (DARA) 1.4 > 10,000 BMS-19384 > 10,000 2 Irbesartan (Avapro) Endothelin IC50 (nm, human) Angiotensin IC50 (nm, human) Compound Irbesartan(Avapro®) AT1 antagonist PS-433540 (DARA) AT1 and ETA antagonist BMS-193884 ETA antagonist Angiotensin group Endothelin

  16. Slide 16: PS433540 – Antihypertensive Activity

    Slide 16: PS433540 – Antihypertensive Activity

    PS433540 reduces blood pressure more than Irbesartan (Avapro) at 30 and 100 mmol/kg Effect of Irbesartan and PS433540 on Mean Arterial BP in Spontaneously Hypertensive Rats (SHR) PS433540 – Antihypertensive Activity PS433540

  17. Slide 17: New Treatment Options

    Slide 17: New Treatment Options

    New Treatment Options Antihypertensive effect of PS433540 would support potential in hypertension and diabetic kidney disease Opportunity for DARA to be an attractive option in hypertension and kidney disease Combine ARB and ERA activity in a single compound, once-a-day pill Avoid polypharmacy typic

  18. Slide 18: Early Clinical Evaluation

    Slide 18: Early Clinical Evaluation

    Early Clinical Evaluation Phase 1 Safety and Pharmacology in Healthy Subjects Establish Safety SAD (Single Ascending Dose) – up to 6 dose levels MAD (Multiple Ascending Dose) – up to 4 dose levels Confirm Dual Activity Mechanism Angiotensin Challenge in Healthy Volunteers Endothelin Challenge in Hea

  19. Slide 19: Single Ascending Dose Study Complete

    Slide 19: Single Ascending Dose Study Complete

    Single Ascending Dose Study Complete Double-blind, randomized, placebo-controlled study to assess safety and tolerability after oral administration of single escalating doses to healthy male subjects Protocol Outline 7 groups – placebo, 20, 50, 100, 250, 500, 1000 mg 8 subjects per cohort – six PS43

  20. Slide 20: DARA Development Schedule

    Slide 20: DARA Development Schedule

    DARA Development Schedule Complete data and material transfer from BMS 2Q-06 Synthesis of 2 Kg GMP of active ingredient (API) 3Q-06 Pre-IND meeting with FDA 08/15/06 3Q-06 Submit IND 12/28/06 1Q-07 ‘First in man’ dosing 02/13/07 1Q-07 Complete AII challenge study Mid-07 Complete ET challenge study 3

  21. Slide 21: Agenda for Today

    Slide 21: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

  22. Slide 22: Strategic Partnerships

    Slide 22: Strategic Partnerships

    Strategic Partnerships Late stage optimization programs Upfront $15 million technology access fee Up to $35 million per program in milestones Double-digit royalties Builds portfolio and financial runway Pharmacopeia prosecutes Phase 1 and Phase 2 Non-dilutive tranched funding - $15 million Up to $83

  23. Slide 23: Strategic Partnerships - Wyeth JAK3 Alliance

    Slide 23: Strategic Partnerships - Wyeth JAK3 Alliance

    Strategic Partnerships Alliance to develop and commercialize JAK3 Inhibitors for Immunological and Inflammatory Diseases Upfront payment for discovery phase program - $5 million Up to $9MM in research funding over 3 years Up to $175MM in preclinical, clinical and commercialization milestones Double-

  24. Slide 24: Strategic Partnerships - Organon Alliance

    Slide 24: Strategic Partnerships - Organon Alliance

    Strategic Partnerships New Alliance to discover and develop candidates with an option to co-commercialize therapeutic products Upfront payment for discovery collaboration - $15 million Research funding over 5 years - $20 million Buy-up option to co-develop and co-commercialize Preclinical, clinical

  25. Slide 25: Agenda for Today

    Slide 25: Agenda for Today

    Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 p38 kinase inhibitor approaching Phase 2 DARA in Phase 1 Strong strategic partnerships Organon strategic alliance with co-commercialization option Wyeth R&D agreement on JAK3 inhibitors GlaxoSmithKline Research & Development al

  26. Slide 26: Financial Summary

    Slide 26: Financial Summary

    Financial Summary For the year ended December 31st, 2006 $16.9 million in net revenue $ 27.8 million in net loss (including $2.0 million non-cash charge) Cash, Cash Equivalents and Marketable Securities $46.1 million as of December 31, 2006 $20 million upfront payments from Wyeth and Organon in 1Q-0

  27. Slide 27: Stock Information

    Slide 27: Stock Information

    Stock Information Stock Exchange: NASDAQ Stock Symbol: PCOP Shares Outstanding (03/09/2007): 21.3 million 52- Week Range: $3.56 - $6.51 Daily Trading Volume (04/05/2007)*: >80,000 shares Market Capitalization (04/05/2007): ~ $125 million Enterprise Value**: ~ $60 million *Trailing 30-day average **C

  28. Slide 28: Pharmacopeia Today

    Slide 28: Pharmacopeia Today

    Pharmacopeia Today DARA Phase 1 clinical development on-going First-in-class approach to significant markets Hypertension Diabetic Nephropathy Partnered clinical programs advancing CXCR2 antagonist in Phase 2 for COPD (partnered with Schering-Plough) p38 kinase inhibitor for inflammatory disease – a

  29. Slide 29: Discovering excellence, driving clinical success

    Slide 29: Discovering excellence, driving clinical success

    Discovering excellence, driving clinical successTM

Source: SEC EDGAR · 8-K filed Apr 11, 2007

More decks from Pharmacopeia Inc